Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OpACIN-neo / PRADO neoadjuvant ipilimumab + nivolumab study in stage III melanoma
NL-OMON50672Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipilimumab and nivolumab in melanoma and cutaneous malignancy (4 arms), sponsored by Netherlands Cancer Institute. Started Nov 2016; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON50672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50672.